Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes.
NSTEMI
STEMI
cardiogenic shock
prognosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
20 Jun 2022
20 Jun 2022
Historique:
received:
30
05
2022
revised:
12
06
2022
accepted:
17
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term outcomes of CS relative to the ST pattern on admission. In a prospective registry of 4647 AMI patients admitted to the intensive cardiac care unit of a university hospital between 2010 and 2019, we compared the clinical characteristics, 30-days case fatality, and long-term outcomes of AMI-CS, based on the presence of ST-segment deviation. AMI-CS developed in 239 (5.1%) patients (26.4% women): 190 (79.5%) STEMI-CS and 49 (20.5%) NSTEMI-CS. The mean age was 69.7 years. The STEMI-CS patients had larger infarcts and more mechanical complications than the NSTEMI-CS patients. The NSTEMI-CS patients had a greater prevalence of hypertension, diabetes, peripheral vascular disease, previous cardiovascular comorbidities, three-vessel disease, and left main disease than the STEMI-CS patients. The STEMI-CS patients had higher 30-day mortality than the NSTEMI-CS (59.5% vs. 36.7%;
Identifiants
pubmed: 35743628
pii: jcm11123558
doi: 10.3390/jcm11123558
pmc: PMC9224589
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Heart Fail. 2015 May;17(5):501-9
pubmed: 25820680
EuroIntervention. 2021 Feb 05;16(15):e1237-e1244
pubmed: 32624460
PLoS One. 2021 Nov 17;16(11):e0259268
pubmed: 34788296
Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):708-15
pubmed: 24221834
J Am Coll Cardiol. 2017 Apr 18;69(15):1913-1920
pubmed: 28408020
Catheter Cardiovasc Interv. 2019 Feb 15;93(3):373-379
pubmed: 30280472
Eur Heart J. 2012 Oct;33(20):2551-67
pubmed: 22922414
Eur Heart J. 2007 Oct;28(20):2525-38
pubmed: 17951287
Am J Cardiol. 2011 Oct 15;108(8):1061-7
pubmed: 21791326
Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):117-25
pubmed: 26884615
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Int J Cardiol. 2011 Oct 6;152(1):70-7
pubmed: 20684999
J Clin Med. 2020 Jul 27;9(8):
pubmed: 32727034
Am J Cardiol. 2019 Dec 15;124(12):1841-1850
pubmed: 31685215
N Engl J Med. 2012 Oct 4;367(14):1287-96
pubmed: 22920912
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
J Am Coll Cardiol. 2000 Sep;36(3 Suppl A):1063-70
pubmed: 10985706
Eur Heart J. 2004 Feb;25(4):322-8
pubmed: 14984921
Am J Cardiol. 2007 Jul 15;100(2):190-5
pubmed: 17631068